FMP
Baudax Bio, Inc.
BXRX
NASDAQ
Inactive Equity
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
0.0218 USD
0.0015 (6.88%)
About
ceo
Dr. Geraldine A. Henwood Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.baudaxbio.com
exchange
NASDAQ
Description
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
CIK
0001780097
ISIN
US07160F4046
CUSIP
07160F206
Address
490 Lapp Road
Phone
484 395 2440
Country
US
Employee
9
IPO Date
Nov 14, 2019
Key Executives
